Condition: Immunotherapy · HCC - Hepatocellular Carcinoma · Sponsor: Michael Dill
The interventional, randomized, placebo-controlled, double-blind phase II-trial FLORA will assess safety and immunogenicity of fecal microbiota transfer in combination with standard of care immunotherapy in advanced hepatocellular carcinoma (HCC) in a parallel group design. Subjects will be randomized 2:1 into either the FMT or placebo group.
This description comes directly from the study's public registry record.
Michael T Dill, PhD · 06221 568611 · michael.dill@med.uni-heidelberg.de
Conrad Rauber, MD/PhD · 06221568611 · conrad.rauber@med.uni-heidelberg.de
Always discuss trial participation with your own doctor first.
| University Hospital Heidelberg | Heidelberg, Baden-Wurttemberg, Germany | Recruiting |
| University Hospital Augsburg | Augsburg, Germany | Not Yet Recruiting |
| University Hospital Essen | Essen, Germany | Not Yet Recruiting |
| University Hospital Mannheim | Mannheim, Germany | Not Yet Recruiting |
| University Hospital Regensburg | Regensburg, Germany | Not Yet Recruiting |
| University Hospital Tübingen | Tübingen, Germany | Not Yet Recruiting |
| University Hospital Ulm | Ulm, Germany | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05690048